With the Rise of GLP-1 Agonists for Treating Obesity, Will Access Challenges Prevent Progress?

Posted on March 2, 2024 by admin

JAMA commentary suggests that issues such as high costs, access, and equity will stop patients from obtaining GLP-1 agonists to treat obesity.